

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM372206

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Glaxo Group Limited		03/02/2015	CORPORATION: ENGLAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Novartis Pharma AG		
<b>Street Address:</b>	Lichtstrasse 35		
<b>City:</b>	4056 Basel		
<b>State/Country:</b>	SWITZERLAND		
<b>Postal Code:</b>	07936		
<b>Entity Type:</b>	CORPORATION: SWITZERLAND		
<b>PROPERTY NUMBERS Total: 17</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2901813	ARRANON	
<b>Registration Number:</b>	4448207	MEKINIST	
<b>Registration Number:</b>	3976964	RAFINLAR	
<b>Registration Number:</b>	3976920	TAFINLAR	
<b>Registration Number:</b>	3763858	ARZERRA	
<b>Registration Number:</b>	3842291	ARZERRA	
<b>Registration Number:</b>	3836755	ORCHARRD	
<b>Registration Number:</b>	2940716		
<b>Registration Number:</b>	3976952	TARFINLAR	
<b>Registration Number:</b>	1592702	ZOFRAN	
<b>Registration Number:</b>	2353902	ZOFRAN ODT	
<b>Registration Number:</b>	4002759	VITALLINKS IN BREAST CANCER	
<b>Registration Number:</b>	4002760	VITALLINKS IN BREAST CANCER	
<b>Serial Number:</b>	85646710		
<b>Serial Number:</b>	85646704		
<b>Serial Number:</b>	85918710	VITALLINKS IN MELANOMA	
<b>Serial Number:</b>	85801653		
<b>CORRESPONDENCE DATA</b>			

OP \$440.00 2901813

**Fax Number:** 9198618913

***Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***

**Phone:** 9198618903

**Email:** mtepper@teiplaw.com

**Correspondent Name:** Tepper & Eyster, PLLC

**Address Line 1:** 3724 Benson Drive

**Address Line 4:** Raleigh, NORTH CAROLINA 27609

**DOMESTIC REPRESENTATIVE**

**Name:** Novartis Pharmaceuticals Corporation

**Address Line 1:** One Health Plaza, Building 430

**Address Line 4:** East Hanover, NEW JERSEY 07936

<b>NAME OF SUBMITTER:</b>	Maury M. Tepper, III
---------------------------	----------------------

<b>SIGNATURE:</b>	/Maury M. Tepper, III/
-------------------	------------------------

<b>DATE SIGNED:</b>	02/05/2016
---------------------	------------

**Total Attachments: 2**

source=Assignment\_Glaxo Group Limited to Novartis Pharma AG#page1.tif

source=Assignment\_Glaxo Group Limited to Novartis Pharma AG#page2.tif

United States of America

ASSIGNMENT OF TRADEMARKS

This Assignment of Trademarks (this "Assignment") dated effective as of 2<sup>nd</sup> March, 2015 (the "Effective Date"), is from Glaxo Group Limited, incorporated in England and Wales with an address of 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the "Assignor"), to Novartis Pharma AG, a Swiss corporation with an address of Lichtstrasse 35, 4056 Basel, Switzerland (the "Assignee").

WITNESSETH:

*WHEREAS*, Assignor is the record owner of the trademarks and the related United States registrations for the marks listed on Exhibit A, attached to this Assignment and incorporated herein (collectively, the "Marks"); and

*WHEREAS*, pursuant to that certain Intellectual Property Assignment Agreement, dated 2<sup>nd</sup> March, 2015, Assignor agreed to assign, transfer and convey to Assignee all right, title and interest in and to the Marks, together with the goodwill of the business, and all common law rights, associated with the Marks; and

*WHEREAS*, Assignor and Assignee desire to confirm and record the assignment of the Marks;

*NOW, THEREFORE*, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Assignor hereby assigns, transfers and conveys to Assignee all right, title and interest in and to the Marks, together with (1) the goodwill of the business symbolized by the Marks, (2) any and all common law rights, title and interest associated with the Marks, and (3) all causes of action, claims and demands and other rights for, or arising from, any infringement, including past infringements, of the Marks.

2. Assignor further agrees, without further consideration, to cause to be performed such other lawful acts and to be executed such confirmatory assignments and other legal documents as Assignee, or its counsel, may from time to time reasonably request to effect fully this Assignment and to permit Assignee to be duly recorded as the registered owner of each of the rights hereby conveyed.

*IN WITNESS WHEREOF*, the Assignor has executed this Assignment on the date set forth below, but effective as of the Effective Date.

ASSIGNOR:

Glaxo Group Limited

By: Jeanne Green

Title: \_\_\_\_\_

Date: \_\_\_\_\_

ASSIGNEE:

NOVARTIS PHARMA AG

By: Christoph Klamp  
As Authorized Signatory

Title: \_\_\_\_\_

Date: 27<sup>th</sup> January 2016

United States of America

Exhibit A to Assignment of Trademarks

<u>Mark</u>	<u>Reg. No.</u>	<u>Reg. Date</u>
ARRANON	2901813	11/9/2004
MEKINIST	4448207	12/10/2013
RAFINLAR	3976964	6/14/2011
TAFINLAR	3976920	6/14/2011
ARZERRA	3763858	3/23/2010
ARZERRA (Stylized)	3842291	8/31/2010
ORCHARRD	3836755	8/24/2010
PINK RIBBON device	2940716	4/12/2005
TARFINLAR	3976952	6/14/2011
ZOFRAN	1592702	4/24/1990
ZOFRAN ODT	2353902	5/30/2000
VITALLINKS IN BREAST CANCER	4002759	7/26/2011
VITALLINKS IN BREAST CANCER	4002760	7/26/2011

<u>Mark</u>	<u>Serial No.</u>	<u>Filing Date</u>
MEKINIST Design	85646710	6/8/2012
TAFINLAR Design	85646704	6/8/2012
VITALLINKS IN MELANOMA	85918710	4/30/2013
RAFINLAR/MEKINIST Gryphon Design	85801653	12/13/2012